Aptiv Solutions to be Acquired by ICON

Combined companies provide unrivalled capabilities for adaptive and medical device trials worldwide Reston, Virginia, 31st March, 2014 – Aptiv Solutions, a global biopharmaceutical and medical device development services company leading the design and implementation of innovative approaches that improve data quality, efficiency, and productivity of product development today announced that it has agreed, subject to … continue reading

Aptiv Solutions Enables First Surrogate Endpoint-Based Adaptive Clinical Trials

Launch of ADDPLAN® 6.1 to Expedite and Improve Decision-Making in Clinical Trials  Reston, Virginia, March 18, 2014 – Aptiv Solutions, a global biopharmaceutical and medical device development services company leading the design and implementation of innovative approaches that improve data quality, efficiency, and productivity of product development, today announced the release of ADDPLAN® 6.1, the … continue reading

Aptiv Solutions Launches New Process for Management of Endpoint Adjudication

Streamlined process will improve efficiency and quality of data collection Reston, Virginia, February 25, 2014 – Aptiv Solutions, a global biopharmaceutical and medical device development services company leading the design and implementation of innovative approaches that improve data quality, efficiency and productivity of product development, today announced the launch of a new, streamlined process to … continue reading

Novartis, Janssen Pharmaceuticals, Eli Lilly and Aptiv Solutions Form a Consortium to Develop Technologies for Design and Execution of Adaptive Dose Finding Trials

Collaboration will create methodologies to drive improved decision-making in exploratory phase development  Reston, Virginia, February 18, 2014 – Aptiv Solutions, a global biopharmaceutical and medical device development services company leading the adoption of innovative clinical trial approaches such as adaptive design, today announced that Novartis Pharma AG, Janssen Pharmaceuticals Inc, and Eli Lilly have joined them … continue reading

Japan’s PMDA Licenses Aptiv Solutions ADDPLAN® Software Suite for Clinical Trial Data Evaluation

Reston, Virginia, February 12, 2014 – Aptiv Solutions, a global biopharmaceutical and medical device development services company leading the adoption of innovative clinical trial approaches such as adaptive design, today announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has purchased a global license for the ADDPLAN® platform, which it will use to evaluate both … continue reading

FDA, EMA Extend Licenses for Aptiv Solutions ADDPLAN® Software for Clinical Trials

FDA Purchases Novel ADDPLAN® DF Software for Improved Evaluation of Phase II Dose-Finding Trials Reston, Virginia, January 7, 2014 – Aptiv Solutions, a global biopharmaceutical and medical device development services company leading the adoption of innovative clinical trial approaches such as adaptive design, today announced the U.S. Food and Drug Administration (FDA) has purchased licenses … continue reading

Aptiv Solutions Enhances its AptivInSite™ Risk-Based Monitoring Offering with ‘Verification by Statistical Sampling’ to Improve Data Quality and Reduce Costs

Reston, Virginia, November 5, 2013 – Aptiv Solutions, a global biopharmaceutical and medical device development services company and leader in adaptive clinical trials, today announced the integration of ‘Verification by Statistical Sampling’ into AptivInSite™ to improve data quality and more reliably deliver on the cost savings achievable through risk-based monitoring. AptivInSite™ is an umbrella methodology … continue reading

Aptiv Solutions ADDPLAN® DF is the First Validated Software to Use MCP-Mod Methodology, Recently Qualified by EMA for Reducing Bias and Error in Dose Finding Clinical Trials

Reston, Virginia, October 29, 2013 – Aptiv Solutions, a global biopharmaceutical and medical device development services company and leader in adaptive clinical trials, today announced that the European Medicines Agency (EMA) has issued a qualification opinion finding that the MCP-Mod1 methodology for dose finding provides the potential to “enable more informative Phase II study designs” … continue reading

Aptiv Solutions Launches ADDPLAN® DF for Optimizing Dose Selection in Phase 2 Trials

Reston, Virginia, September 17, 2013 – Aptiv Solutions, a global biopharmaceutical and medical device development services company and leader in adaptive clinical trials, today announced the release of ADDPLAN® DF, innovative software that designs, simulates, and analyzes Phase 2 dose finding studies to make them more efficient and effective. ADDPLAN® DF is the latest product … continue reading

Aptiv Solutions Appoints Patricia Monteforte, CRO Executive and Entrepreneur, as President of Trio Clinical Resourcing

Reston, Virginia, August 20, 2013 – Aptiv Solutions, a global biopharmaceutical and medical device development services company and leader in adaptive clinical trials, announced today the appointment of Patricia Monteforte to the role of President of Trio Clinical Resourcing, an Aptiv Solutions subsidiary devoted to clinical and regulatory staffing. Ms. Monteforte will leverage more than … continue reading

Related Posts Plugin for WordPress, Blogger...